Evolus(EOLS) - 2024 Q4 - Annual Results

Evolus Announces Preliminary Unaudited Fourth Quarter and Full-Year 2024 Net Revenue, Achieving Record Results at the Top of the Company's Guidance Expects U.S. Approval Within 90 Days for Evolysse Form and Evolysse™ Smooth Injectable Hyaluronic Acid Gels ™ Provides 2025 Guidance and Maintains Projection for Full-Year 2025 Profitability 1 NEWPORT BEACH, Calif., January 21, 2025 – Evolus, Inc. (NASDAQ: EOLS), a global performance beauty company with a focus on building an aesthetic portfolio, today announced ...